Yale University
New Haven, Connecticut, 06520, United States
NCT Number: NCT03542682
Rapid Action Insulin (RAI) absorption and action measured by time to reach maximum insulin concentration and glucose infusion rate.
Looking for future studies?
Notify Me18 year–30 year
All sexes
Interventional
Not applicable
New Haven, Connecticut, 06520, United States
The investigators hypothesize that RAI absorption and action measured by time to reach maximum insulin concentration and glucose infusion rate during the clamp study will be significantly faster when insulin bolus is delivered using the "Quick Bolus" feature as compared to the "Standard Bolus".
Outcomes were updated at time of results entry.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via "quick bolus" of 15 units per minute during a euglycemic clamp.
Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via "standard bolus" of 1.5 units per minute during a euglycemic clamp.
Time frame: 300 minutes
time to maximum glucose infusion rate (GIR) in minutes
Time frame: up to 5 hours
Time to reach baseline insulin concentrations is used to determine the completion of insulin as part bolus of bioavailability.
Time frame: 300 minutes
maximum glucose infusion rate (GIRmax)
Time frame: 300 minutes
area under the curve for the glucose infusion rate
Yale University
Other
The Effect of Insulin Bolus Speed of Rapid-Acting Insulin Analog Absorption and Action in Individuals With Type 1 Diabetes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03761186
Autoimmune Diseases, Diabetes Mellitus
Stockholm, Sweden
View Trial DetailsNCT05557227
Glucose Metabolism Disorders, Hyperglycemia
Aarhus, Region Midt, Denmark
View Trial DetailsNCT06115616
Type1diabetes
Aarhus, Denmark
View Trial DetailsNCT05662267
Autoimmune Diseases, Chronic Disease
Lille, France
View Trial Details